- Home
- ICCM vs BEAT Comparison
ICCM vs BEAT Comparison
Compare ICCM & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- BEAT
- Stock Information
- Founded
- ICCM 2006
- BEAT 2015
- Country
- ICCM Israel
- BEAT United States
- Employees
- ICCM N/A
- BEAT N/A
- Industry
- ICCM
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ICCM
- BEAT Technology
- Exchange
- ICCM Nasdaq
- BEAT Nasdaq
- Market Cap
- ICCM 55.8M
- BEAT 51.1M
- IPO Year
- ICCM N/A
- BEAT 2021
- Fundamental
- Price
- ICCM $0.99
- BEAT $1.35
- Analyst Decision
- ICCM Strong Buy
- BEAT Buy
- Analyst Count
- ICCM 1
- BEAT 1
- Target Price
- ICCM $2.50
- BEAT $8.00
- AVG Volume (30 Days)
- ICCM 278.9K
- BEAT 175.9K
- Earning Date
- ICCM 08-19-2025
- BEAT 08-13-2025
- Dividend Yield
- ICCM N/A
- BEAT N/A
- EPS Growth
- ICCM N/A
- BEAT N/A
- EPS
- ICCM N/A
- BEAT N/A
- Revenue
- ICCM $3,273,000.00
- BEAT N/A
- Revenue This Year
- ICCM $83.41
- BEAT N/A
- Revenue Next Year
- ICCM $185.02
- BEAT N/A
- P/E Ratio
- ICCM N/A
- BEAT N/A
- Revenue Growth
- ICCM 0.34
- BEAT N/A
- 52 Week Low
- ICCM $0.48
- BEAT $1.21
- 52 Week High
- ICCM $1.66
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ICCM 46.56
- BEAT 37.47
- Support Level
- ICCM $0.81
- BEAT $1.49
- Resistance Level
- ICCM $1.03
- BEAT $1.62
- Average True Range (ATR)
- ICCM 0.06
- BEAT 0.11
- MACD
- ICCM 0.01
- BEAT -0.02
- Stochastic Oscillator
- ICCM 75.00
- BEAT 7.44
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.